← back to search

Charles M. Rudin

New York Proton Center · US
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
CU-WCGS Linkage Program Summer Undergraduate Research Toggle Summer Undergraduate Research menu options ACCESS Summer Internship Program Pre-Doctoral Institutional Training Programs Student Experience Toggle Student Experience menu options Alumni Contact Information Form Student Services Toggle Student Services menu options Student Government (GSEC) Toggle Student Government (GSEC) menu options Board Games Club Student Services and Wellbeing Resources Hub Thesis & Dissertation: Guidelines for Masters and PhD Programs WCGS Positive Learning Environment & Student Mistreatment Policy Access and Belonging Toggle Access and Belonging menu options Weill Cornell IMSD Program ACCESS Summer Internship Program Esprit de Corps Student Clubs and Initiatives Toggle Student Clubs and Initiatives menu op
h-index
134
citations
87,478
works
1,682
NIH funding
primary concept
email

Recent publications

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
New England Journal of Medicine 2025cited by 157position: lastdoi
Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer
Nature 2025cited by 20position: middledoi
Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors
The Oncologist 2025cited by 9position: middledoi
Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.
Journal of Clinical Oncology 2025cited by 9position: firstdoi
The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models
Cancer Research 2025cited by 1position: middledoi
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
Cancer Cell 2024cited by 149position: middledoi
Automated real-world data integration improves cancer outcome prediction
Nature 2024cited by 140position: middledoi
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancer
Science Advances 2024cited by 57position: middledoi
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy
npj Precision Oncology 2024cited by 50position: middledoi
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
The Lancet Oncology 2024cited by 46position: middledoi
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies
Cancer Cell 2024cited by 46position: middledoi
Chromothripsis-Mediated Small Cell Lung Carcinoma
Cancer Discovery 2024cited by 43position: lastdoi
ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer
Science Advances 2024cited by 39position: middledoi
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study
Molecular Cancer 2024cited by 38position: middledoi
Lung cancer research and treatment: global perspectives and strategic calls to action
Annals of Oncology 2024cited by 37position: middledoi
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non–Small-Cell Lung Cancer
Journal of Clinical Oncology 2024cited by 32position: middledoi
SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing
Journal of Hematology & Oncology 2024cited by 32position: lastdoi
Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity
Trends in cancer 2024cited by 31position: lastdoi
Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions
Science Advances 2024cited by 27position: middledoi
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Clinical Cancer Research 2024cited by 27position: lastdoi
CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation
Signal Transduction and Targeted Therapy 2024cited by 23position: lastdoi
A Lung Cancer Mouse Model Database
bioRxiv (Cold Spring Harbor Laboratory) 2024cited by 1position: middledoi
IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
Journal of Clinical Investigation 2023cited by 164position: middledoi
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Journal of Hematology & Oncology 2023cited by 149position: firstdoi
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade
Cancer Cell 2023cited by 134position: middledoi
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance
Cell Reports 2023cited by 124position: middledoi
Genomic mapping of metastatic organotropism in lung adenocarcinoma
Cancer Cell 2023cited by 87position: middledoi
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation
Journal of Thoracic Oncology 2023cited by 84position: firstdoi
Alveolar Differentiation Drives Resistance to <i>KRAS</i> Inhibition in Lung Adenocarcinoma
Cancer Discovery 2023cited by 64position: middledoi
Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies
Nature Immunology 2023cited by 56position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

John T. Poirier · NYU Langone Health26 papers (2015–2024)Mark G. Kris · Kettering University24 papers (2013–2022)Maria E. Arcila · Molecular Oncology (United States)19 papers (2013–2022)Marc Ladanyi · Center for Cancer Research19 papers (2013–2024)Gregory J. Riely · Weill Cornell Medicine18 papers (2013–2022)Natasha Rekhtman · Kettering University16 papers (2015–2024)Elisa de Stanchina · European Molecular Biology Laboratory16 papers (2015–2024)Helena A. Yu · University of California, San Diego15 papers (2015–2023)Matthew D. Hellmann · Weill Cornell Medicine15 papers (2014–2024)Alexander Drilon · Université Grenoble Alpes13 papers (2015–2025)Michael Offin · RIKEN BioResource Research Center13 papers (2018–2024)Àlvaro Quintanal-Villalonga · Research Institute Hospital 12 de Octubre13 papers (2019–2024)Ai Ni · Center for Drug Evaluation and Research12 papers (2016–2022)Bob T. Li · Presbyterian Hospital11 papers (2018–2024)Lauren A. Byers · The University of Texas MD Anderson Cancer Center10 papers (2014–2024)Triparna Sen · University of British Columbia10 papers (2020–2024)Ramaswamy Govindan · Huntsman Cancer Institute8 papers (2015–2025)Andrew J. Plodkowski · Manhattan Scientifics (United States)8 papers (2016–2022)David B. Solit · New York Oncology Hematology7 papers (2014–2020)Hira Rizvi · AstraZeneca (United States)7 papers (2018–2022)